Goodwin Guides Royalty Pharma on Acquisition of Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones
January 06, 2026
January 06, 2026
BOSTON, Massachusetts, Jan. 6 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:
* * *
Goodwin Guides Royalty Pharma on Acquisition of Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones
*
The Life Sciences team guided Royalty Pharma plc (Nasdaq: RPRX) on the acquisition of the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 mill . . .
* * *
Goodwin Guides Royalty Pharma on Acquisition of Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones
*
The Life Sciences team guided Royalty Pharma plc (Nasdaq: RPRX) on the acquisition of the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 mill . . .